Functional studies of genetic variants of unknown significance by Lança, Miguel Filipe Cecília
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mestrado em Biologia Molecular e Genética   
  
 
 
 
 
 
 
 
 
 
  
UNIVERSIDADE DE LISBOA 
FACULDADE DE CIÊNCIAS 
DEPARTAMENTO DE BIOLOGIA 
VEGETAL 
 
Functional studies of genetic 
variants of unknown 
significance 
 
Miguel Filipe Cecília Lança 
Dissertação orientada por: 
Professora Doutora Susana Nunes da Silva 
Professor Rui Artur Paiva Loureiro Gomes  
2019 
II 
 
AGRADECIMENTOS 
 
Este último percurso académico, que culminou na elaboração deste trabalho não teria sido 
possível sem o empenho e estímulo de diversas pessoas. Gostaria de expressar toda a minha gratidão e 
apreço a todos aqueles que, direta ou indiretamente, contribuíram para que esta tarefa se tornasse uma 
realidade, e que influenciaram a minha viagem académica e crescimento a nível pessoal. A todos quero 
manifestar os meus sinceros agradecimentos. 
Em primeiro lugar, um especial agradecimento à minha orientadora Professora Doutora Susana 
Nunes da Silva, para quem não há agradecimentos que cheguem e que foi mais do que uma orientadora 
para mim. Por todo o apoio e ensinamentos ao longo deste ano, pela liberdade de ação que me permitiu, 
de forma decisiva para que este trabalho contribuísse para o meu desenvolvimento pessoal. 
Ao Professor Sebastião Rodrigues, o modo como se disponibilizou no auxílio dos trabalhos e 
pela partilha do seu conhecimento e experiência. 
Ao Professor José Rueff, por me receber no ToxOmics e pela amabilidade e gentileza que 
sempre demonstrou, pelo interesse, preocupação e disponibilidade por ajudar e partilhar o seu 
conhecimento e experiência. 
Às minhas companheiras de laboratório, principalmente à Maria João Pires e à Mónica Honrado 
por se terem tornado grandes amigas durante este ano e por toda a ajuda que disponibilizaram tanto a 
nível de elaboração deste trabalho, como a nível pessoal. 
À Cláudia Andrade por toda a ajuda e disponibilidade no manuseamento da aparelhagem da 
citometria de fluxo. 
  Às meninas da nutrição por toda a conversa e alegria que transmitiam. 
Ao grupo do laboratório 2.16, mais concretamente Bruno Gomes, Francisco Esteves e Marisa 
Cardoso, que sempre se disponibilizou para ajudar no trabalho e me apoiar incansavelmente a nível 
pessoal. 
À Rita Lourenço pela paciência e partilha de ensinamentos e experiências que transmitiu na 
execução deste trabalho. 
Aos meus amigos que nunca estiveram ausentes, agradeço a amizade e carinho que sempre me 
disponibilizaram. 
Por último, e sem dúvida mais importante, um eterno agradecimento à minha família pelo apoio 
incondicional que me deram toda a vida, que sempre acreditou no meu potencial e que sem eles ao meu 
lado não teria conseguido atingir os meus objetivos. Um especial agradecimento aos meus pais e avós 
por sempre demonstrarem orgulho e carinho por mim e por acreditarem sempre em mim, nos bons e 
maus momentos da vida, e que sem eles eu não estaria onde estou hoje. À minha querida irmã Margarida, 
que mais do que uma irmã, é uma amiga para todas as ocasiões da vida. 
A todos, muito obrigado por permitirem que esta tese seja uma realidade. 
III 
 
FUNDING 
 
 This study has been supported by funding through a Terry Fox 2017 grant from Liga Portuguesa 
Contra o Cancro (LPCC). 
 
  
IV 
 
ABSTRACT 
 
Breast cancer is the second most commonly diagnosed cancer worldwide and the most common 
cancer among women. It is the family history or genetic predisposition the most important factor of 
breast cancer risk. In fact, 5-10% of cancer cases are hereditary breast cancer (HBC), and mainly of 
them are associated with inherited mutations in BRCA1 and BRCA2 genes. These genes are involved in 
both the main DNA DSB repair pathways - non-homologous end-joining (NHEJ) and, the most 
important, homologous recombination (HR). So, mutations in these genes could cause defectives in 
DNA repair, and because of that, cells that suffer serious unrepaired damage might triggers the 
development of breast cancer. To avoid that, it is very important to perform clinically a genetic testing, 
which could identify individuals and families with genetic predisposition to developing cancer, like 
mutations in BRCA1 and BRCA2. Unfortunately, in 12%-13% of the patients tested for BRCA1/2 
mutations, are detected VUS, or variants of uncertain significance, which does not know if the variant 
is either benign or pathogenic, which generates significant problems in risk evaluation, counselling and 
preventive care. To overcome this problem, several functional assays have been or are being developed 
to clarify its mutational status. Our goal with this study is a functional evaluation of the role of VUS 
previously identified, in drug response (Doxorubicin). To doing so, we performed a proof of concept 
functional analysis using Peripheral Blood Mononuclear Cells (PBMCs) collected by venous puncture 
from four Portuguese volunteers: two VUS-carriers patients in the BRCA1 gene and two negative 
controls. In this study we selected 4 techniques to assess the cellular response to lesions induced by 
Doxorubicin: TUNEL assay, Caspases activity assay, H2Ax assay and Comet assay. 
The results from TUNEL assay and Caspases activity assay had some differences between each 
other, mainly due the existence of intra-individual variability, what makes essential to perform another’s 
assays. The results for H2Ax and Comet assays besides showing intra- and inter-individual 
variabilities, showed an increase of sensitivity possibly associated with a defective in DNA repair for 
VUS-carriers, after exposure to increased doses of doxorubicin. In fact, except TUNEL assay, all 
techniques show this sensitivity when the samples were treated with Doxorubicin. However, and mainly 
because of the existence of genetic variability additional assays and studies should be performed to 
understand the results obtained and to possibly characterize the highly frequent VUS in cancer-related 
genes and give us some answers about breast cancer risk. 
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RESUMO 
 
Mundialmente a segunda causa mais comum de morte pertence ao cancro, um grupo de doenças 
relacionada com uma grande instabilidade genómica e que leva a um crescimento descontrolado de 
células anormais. Incluído na vasta gama de cancros, o cancro da mama está no segundo lugar de cancros 
mais comuns diagnosticados globalmente, sendo ainda o mais comum entre as mulheres. Dentro de 
diversos fatores como estilo de vida, dieta, intervenções médicas de longo prazo, sexo e etnia da pessoa 
e base genética, o fator mais importante que eleva o risco de cancro da mama pertence à história familiar 
ou predisposição genética. De facto, 5%-10% de casos de cancro da mama são hereditários (HBC) e a 
maior parte deles estão associados com mutações herdadas nos genes BRCA1 e BRCA2. Estes genes 
estão envolvidos em ambas as vias de reparação de quebras de dupla cadeia do DNA – união de 
extremidades não-homólogas (NHEJ) e, a mais importante, recombinação homóloga (HR). Logo, 
mutações nestes genes, que contribuem para 20%-25% de risco, podem causar deficiência na reparação 
de DNA, e com isso, células que sofrem sérias lesões, ao não serem reparadas, potencia o aparecimento 
de cancro da mama. Essas lesões têm diversas origens, que podem ir desde processos metabólicos, como 
espécies reativas de oxigénio (ROS), até fatores externos como radiação ou agentes químicos. Para evitar 
isso, é muito importante realizar clinicamente testes genéticos, que podem identificar individualmente 
ou numa família uma predisposição genética para desenvolver cancro, como mutações em BRCA1 e 
BRCA2. Hoje em dia já existe tecnologia que permite uma sequenciação mais completa do genoma e 
que permite fornecer informações a respeito de alteração de regiões de codificação que poderão estar 
associadas ao cancro. Apesar dos custos desta tecnologia, sequenciação de próxima geração (NGS), 
serem ainda altos, uma sequenciação de genes baseada nela é melhor escolha para o diagnóstico de 
alguns pacientes. Contudo, e apesar desta enorme inovação tecnológica, em cerca de 12%-13% dos 
pacientes testados para mutações BRCA1/2 são detetadas VUS, ou variantes de significado 
desconhecido, maioritariamente alterações missense, e que portanto, não se sabe se a variante é benigna 
ou patogénica, o que acaba por gerar problemas significativos na avaliação do risco, aconselhamento e 
cuidado preventivo. Para ultrapassar este problema, diversos ensaios funcionais estão a ser ou vão ser 
desenvolvidos para clarificar o estado mutacional da variante e obter dados que possam prever a 
casualidade da VUS num modelo teórico. Por esse mesmo motivo, e sabendo que a divisão celular pode 
ser tida como alvo para tratar pacientes com cancro, é muito útil o uso de agentes quimioterapêuticos na 
construção destes ensaios funcionais. Estes agentes induzem lesões no DNA que são reconhecidas pelos 
sistemas de reparação e levam à reparação ou morte das células, no entanto de referir, que sendo agentes 
quimioterapêuticos, apenas causam dano no DNA em altas doses. Contudo, tal como o nome sugere, 
nas VUS, é totalmente desconhecido se os mecanismos de reparação de DNA são interrompidos 
aquando de mutações nos genes responsáveis pela sua reparação, como BRCA1 e BRCA2, que por sua 
vez estão ligados a cancro da mama e ovários. Por esse motivo, portadores de VUS diagnosticados com 
cancro metastático da mama ou ovário podem não beneficiar de certas terapias, como inibidores de 
platina ou PARP, que têm como alvo os defeitos do sistema de reparação de DNA, e que são atualmente 
recomendados para indivíduos com variantes patogénicas de BRCA1 ou BRCA2. Daí ser tão importante 
a realização de trabalhos, como este mesmo estudo que permite uma avaliação funcional do papel das 
VUS, previamente identificadas, em resposta a agentes genotóxicos (Doxorubicina).  
Para possibilitar a execução de um estudo funcional a estas VUS previamente sequenciadas, 
realizámos uma “prova de conceito” de análise funcional em Células Mononucleares de Sangue 
Periférico (PBMCs) coletadas por injeção venosa e derivadas de quatro voluntárias portuguesas com um 
diferente diagnóstico para cancro da mama hereditário: dois portadores de VUS para o gene BRCA1 e 
dois controlos negativos. Neste estudo selecionámos quatro técnicas para avaliar a resposta celular a 
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lesões induzidas por Doxorubicina: Ensaio de TUNEL, ensaio de atividade de Caspases, ensaio de 
H2Ax e ensaio do “cometa”. O ensaio de TUNEL é um método de deteção da fragmentação de DNA 
apoptótico in situ, que como é sugerido, identifica tanto células em apoptose, como lesões no DNA, 
quando usado isoladamente. O ensaio de atividade das Caspases permite a deteção de caspases ativas, 
ou seja, de proteases cisteínicas intracelulares e que desempenham papéis fundamentais na via da 
apoptose e inflamação. Desta forma, com este método, ao detetar caspases que estejam ativas estamos 
a detetar diferentes fases de apoptose das células. Em relação à metodologia de H2Ax, é um método 
que se baseia na análise de marcadores para quebras de dupla cadeia do DNA (DSBs). Estes marcadores 
internos, alteram a sua conformação quando o DNA sofre lesões e por esse motivo, ao quantificar esses 
marcadores alterados, é possível quantificar as células afetadas por determinado estímulo. Por último, o 
método do “cometa” possibilita a quantificação de células que sofreram dano no DNA por meio de 
análise da quantidade de DNA que migrou para fora do núcleo quando a mesma célula sofreu um 
determinado estímulo. É a esta migração de DNA que se dá o nome de cometa, visto apresentar uma 
aparência semelhante. Todas estas técnicas, com exceção do método do “cometa” que é analisada 
microscopicamente, são realizadas em citometria de fluxo, uma vez que se trata de uma metodologia 
altamente sensível para avaliação dos resultados.  
Os resultados obtidos provenientes do TUNEL e da atividade de Caspases tiveram algumas 
diferenças entre si, muito devido a variabilidade intra- e inter-individual, o que torna essencial realizar 
novos ensaios. Relativamente ao H2Ax e ao ensaio do cometa, os resultados para além de mostrarem 
as referidas variabilidades, intra- e inter-individuais, também mostra um aumento de sensibilidade 
possivelmente associada com uma deficiência na reparação de DNA com o aumento de dose de 
Doxorubicina, para as amostras de portadores de VUS. De facto, exceto o TUNEL, todas as técnicas 
mostram essa sensibilidade quando as amostras são tratadas com o agente. No que toca aos controlos 
positivos (Camptotecina - CPT e Peróxido de Hidrogénio - H2O2), os resultados não são os mais 
esperados, contudo enquanto nos estudos de apoptose, o CPT mostra níveis de apoptose, mesmo que 
poucos, nos estudos de quantificação de lesão no DNA, a H2O2 mostrou danos elevados em apenas 
algumas amostras, levando a crer novamente a existência de variabilidade inter-individual neste estudo. 
Deste modo, em ensaios futuros é essencial testar a eficiência destes mesmos controlos para um melhor 
controlo e entendimento dos resultados obtidos. Para além disto tudo, estes resultados são o exemplo da 
grande limitação que o uso de células mononucleares de sangue periférico (PBMCs) oferecem a estudos 
deste género, visto que as colheitas intensivas de sangue por injeção são de certo modo, invasivas quer 
para os voluntários, limitando por uma questão ética a obtenção de células a serem usadas nos trabalhos. 
Desta forma, um dos nossos objetivos futuros é o estabelecimento de uma linha imortalizada de 
linfócitos B humanos que poderá ajudar a ultrapassar este problema. Contudo, enquanto as linhas não 
estão prontas e, em grande parte devido à existência de variabilidade genética, devem ser realizados 
mais ensaios e estudos, de forma a compreender melhor os resultados obtidos e para ser possível 
caracterizar as VUS mais frequentes em genes relacionados com cancro e nos dar algumas respostas 
sobre o risco de cancro da mama. 
 
 
 
Palavras-chave: Cancro da mama; BRCA1; Vias de reparação de DNA; VUS; PBMCs; Ensaios 
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1. INTRODUCTION 
 
1.1 CANCERIGENESIS 
 
Cancer is a generic term for a large group of diseases, which it is usually characterized as an 
evolutionary process that results from the accumulation of somatic mutations in normal cells, leading to 
an uncontrolled growth/proliferation of the mutated cells that can invade adjoining parts of the body 
and/or spread to other organs (Blanpain, 2013; WHO, 2014). It is the second leading cause of death 
worldwide and is estimated to account for 9.6 million death in 2018. The most common types of cancer 
in men are lung, prostate, colorectal, stomach and liver cancer, while in women, the most common are 
breast, colorectal, lung, cervix and thyroid cancer (Hassanpour & Dehghani, 2017; WHO, 2014). 
Biologic molecules are very sensitive to spontaneous chemical reactions, mostly hydrolysis, and 
DNA is the most vulnerable, because it cannot simply be replaced, instead of it, it relies on repair of 
existing molecules. It is represented by only one copy in most cells and accumulates numerous lesions 
over a lifetime. The bases in DNA are highly sensitive to chemical modifications, which can cause 
serious damage to DNA molecule. When defective repair and replication errors convert these damages 
into mutations, the changes are permanent and continually exercise their effect, even in successor cells. 
Furthermore, these mutations cause the loss of tumor-suppressor genes and the activation of oncogenes, 
which trigger uncontrolled cellular proliferation and the development of abnormal cells (Hoeijmakers, 
2009; Roos & Kaina, 2006). 
The resultant DNA damage either involve one (single strand break – SSB) or both strands of the 
DNA (double strand break – DSB), which occurs when the sugar-phosphate backbones of both DNA 
strands are broken at a similar position or near one other. While SSBs can be converted to DSBs and be 
repaired, unrepaired DSBs can lead to serious and permanent consequences in cells, once they can be 
mutagenic and affect the expression of multiple genes, and most importantly, be lethal to the cell 
(Nowsheen & Yang, 2013).  
 
 
1.2 DNA DAMAGING AGENTS 
 
DNA can be damaged by products from exogenous processes, such as those from external 
environmental processes, and endogenous processes, from internal metabolic processes. Endogenous 
agents include: reactive oxygen and nitrogen species (ROS and RNS, respectively), formed during 
oxidative stress, metabolic processes and the inflammatory response; depurination and depyrimidination 
at certain loci, which occurs through the hydrolysis of N-glyosidic bonds; and replication stress, which 
occurs during the S phase and causes the stalling of replication forks. On the other turn, exogenous 
agents include: ionizing and solar ultraviolet radiation, which generates, respectively, SSBs and DSBs 
as well as oxidative modifications of nucleobases, and also pyrimidine dimers, which distort the 
structure of the DNA chain and blocks transcription or replication past the site of damage; environmental 
pollutants present in air, water and food; and chemical agents (second-hand smoke, pesticides and toxic 
metals), which are metabolised into highly reactive metabolites that react with nitrogenous bases and 
can lead to deleterious DNA strand breaks and DNA adducts  (Copper, Geoffrey and Hausman, 2007; 
Helena et al., 2018; Hoeijmakers, 2009; Nowsheen & Yang, 2013). 
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To maintain the genomic integrity, cells developed two strategies: DNA damage is repaired or 
tolerated, by DNA damage response (DDR), after detection the above lesions; or cells are removed by 
death, if they possess DNA damage too great or when the repair is ineffective (Nowsheen & Yang, 2013; 
Roos & Kaina, 2006). Basically, after DNA damage, sensor proteins bind to and signal to cell cycle 
checkpoint and DNA damage checkpoint kinases, which will induce cell cycle arrest and start the 
appropriate DNA damage repair pathway to deal with the type of damage present. After that, if the repair 
was successful, the cell survives and resumes replication, if not, cell death or senescence pathways are 
triggered. If the DNA repair mechanisms are defective genomic instability arises, which is one of the 
hallmarks of cancer (Figure 1.1)  (Majidinia & Yousefi, 2017). 
 
 
1.3 DNA REPAIR 
 
The prominent DNA repair mechanisms (Figure 1.2) include mismatch repair (MMR), base-
excision repair (BER), nucleotide-excision repair (NER), and double-strand DNA break repair (DSBR), 
which can be further divided in non-homologous end-joining (NHEJ), homologous recombination (HR), 
and microhomology-mediated end-joining or alternative end-joining (MMEJ), which is an alternate 
NHEJ pathway that commonly results in DNA sequence deletions (Helena et al., 2018). 
Mismatch repair controls the correction of base pair mismatches, which occur when A-G and C-T do 
not pair correctly and, also, corrects DNA insertions and deletions resulting from erroneous DNA 
replication or DNA polymerase misincorporation errors (Helena et al., 2018). 
Base-excision repair (BER) is involved in the removal and replacement of damaged DNA bases, 
resulting from ROS, X-rays, alkylating agents and spontaneous reactions (Helena et al., 2018). 
Nucleotide-excision repair (NER) controls the removal of DNA adducts from DNA by excising an 
oligonucleotide containing the lesion to replace it with newly synthesised DNA, which can be induced 
by UV light and polycyclic aromatic hydrocarbons which contribute to destabilization of the DNA 
double helix (Helena et al., 2018). 
Figure 1.1 - Hallmarks of Cancer (Hanahan & Weinberg, 2011) 
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As mentioned before, the agents that cause DSBs include X-rays, ionizing radiation and anti-
cancer drugs. Briefly, after these breaks been detected some members of the DDR machinery promote 
the formation of foci at sites of DNA damage leading to the recruitment of repair proteins. There are 
two main mechanisms occurring in the DSB repair process, NHEJ and HR. In NHEJ, no sequence 
homology for DSBs end-joining is required, and it involves minimal DNA processing, but when it 
occurs bases may be lost or added, and because of that it is associated with an elevated risk of 
mutagenesis. On the contrary, in HR, sequence homology is required in order to align DSBs ends prior 
to ligation, and because of that HR is the most important error-free DNA DSB repair mechanism. 
Briefly, in HR, replicated sister chromatid DNA sequences are used as templates to restore missing 
DNA sequences on the damaged chromatid, and because of that, it can only operate in the S and G2 
phases of the cell cycle (Helena et al., 2018; Roos & Kaina, 2006). 
 
So whatever is the type of DNA damage, the response to this genomic instability involves 
signalling, checkpoints activation, and repair of the DNA lesions, and therefore the maintenance system 
determines cell’s fate, as mentioned before – survival, replicative senescence, or death, which can occur 
by apoptosis, necrosis or autophagy (Hoeijmakers, 2009; Nowsheen & Yang, 2013; Roos & Kaina, 
2006). Programmed cell death or apoptosis is a physiological mechanism, involving specific 
morphological and biochemical changes such as cell shrinkage, chromatin condensation, protein 
cleavage, DNA breakdown and phagocytosis, while necrosis is a form of cell death that causes 
cytoplasmic swelling, dilution of cytoplasmic organelles, rupture of plasma membrane and some 
chromatin condensation. On the other hand, autophagy occurs without chromatin condensation, and 
forms two-membrane autophagic vacuoles that contain degenerating organelles or cytosol (Papaliagkas, 
Anogianaki, Anogianakis, & Ilonidis, 2007; Roos & Kaina, 2006; Ward et al., 2008). 
 
 
Figure 1.2 - Different types of DNA lesions, their origins, repair pathways and predisposing germline mutations leading 
to cancer. BER, base excision repair; IR, ionizing irradiation; HR, homologous recombination; MMR, mismatch repair; NER, 
nucleotide excision repair; NHEJ, non-homologous end joining; ROS, reactive oxygen species; UV, ultraviolet. (Weeden & 
Asselin-Labat, 2018) 
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1.4 BREAST CANCER 
 
Breast cancer (BC) is a disease in which certain cells from the breast grow and divide 
uncontrollably, which subsequently turn into breast tumor. It is the second most commonly diagnosed 
cancer worldwide and the most common cancer among women, with an estimated 2.1 million cases and 
626 679 deaths in 2018 (Lam & Ervik, 2018; Psyrri, Apostolou, Fostira, Economopoulou, & 
Dimitriadis, 2015). Although BC is much more common in women, it can also develop in men. Its 
development is associated with genetic and environmental factors, or risk factors, which it is defined as 
factors or agents that affects individual’s chance of getting a specific disease, in this case breast cancer. 
As mentioned before, they can be divided into two groups: (a) inherent or genetic factors, such as gender, 
age, race and ethnicity and genetic background; and (b) extrinsic or environmental factors, such as long-
term medical intervention, dietary habits and other factors conditioned by lifestyle (Feng et al., 2018; 
Kamińska, Ciszewski, Łopacka-Szatan, Miotła, & Starosławska, 2015). However, family history or 
genetic predisposition is the most important factor for determining breast cancer risk (de Jong et al., 
2002). Actually, it is the genetic heterogeneity that is passed down under a autosomal dominant 
inheritance and that can be recognized clinically, early onset, by dominant inheritance (Mahdavi et al., 
2019). 
The definition of “familial” breast cancer is not simple, but it is generally accepted a criteria 
that includes: (a) at least three breast and/or ovarian cancer cases in a family; (b) two breast cancer cases 
in close relatives, with at least one case diagnosed before 50 years of age; (c) at least two breast cancer 
cases in a family diagnosed before age 40; (d) any male breast cancer case with a family history of 
ovarian cancer or early start female breast cancer; (e) Ashkenazi Jewish ancestry with breast cancer, 
especially triple-negative breast cancer and diagnosed before 60 years-old; and (f) breast and ovarian 
cancer in the same person (Shiovitz & Korde, 2015). The hereditary breast cancer (HBC) accounts for 
5-10% of cancer cases, while the majority of breast cancers belong to sporadic subtype, which it is 
associated with an increasing accumulation of unrepaired mutations in breast cells that are acquired 
during patients life (Feng et al., 2018; Majidinia & Yousefi, 2017).  
 
 
1.5 BREAST CANCER AND GENETIC PENETRANCE 
 
In HBC, the genetic starting point is based on a hereditary germline mutation that occurs in one 
of the alleles from genes with highly penetrance, followed by a reduction in heterozygosity of somatic 
tissues. The high penetrance genes BRCA1 and BRCA2 account for 20-25% of this risk, almost one-third 
of the inherited BCs. Its proteins take a major part in repairing DSB which can be done by HR. Thus, 
BRCA defective cells are highly susceptible to DNA damage and, consequently, carcinogenesis 
(Mahdavi et al., 2019). In addition to the high penetrance genes, both moderate-penetrance genes, 
additional rare, and low-penetrance alleles, more common, are also associated with hereditary breast 
cancer (Figure 1.3) (Shiovitz & Korde, 2015). 
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1.6 GENETIC TESTING 
 
There are a variety of reasons to perform clinically a genetic testing. They are divided in: (i) 
diagnostic testing, which is done to determine whether a patient with symptoms has a determined 
condition, or what condition they have, if their symptoms are non-specific; (ii) predictive testing or 
genetic risk assessment, which is done usually for people with a family history of a condition for which 
they have not yet presented symptoms, and can lead to clinical interventions, or be useful in life 
planning; and (iii) reproductive testing, which informs parents of the risk of having a child affected with 
a recessive genetic disorder, and determines whether a pregnancy is affected by a genetic condition 
(Hoffman-Andrews, 2017). 
The major purpose of genetic testing is the identification of individuals and families with a 
genetic predisposition to developing cancer, like the identification of tumor suppressor genes associated 
with specific hereditary cancer syndromes, such as BRCA1 and BRCA2 (Carvalho, Couch, & Monteiro, 
2007; Grogan & Kirsch, 1997). This is particularly important to educate at-risk family members about 
their risk and to promote changes in their life style, foster increased surveillance and to allow informed 
decisions about preventive surgery or hormonal therapy (Carvalho et al., 2007; Grogan & Kirsch, 1997). 
Unfortunately, there are limitations on genetic testing, such as the many complexities involved in its 
application, interpretation, clinical significance, and psychological effects to the patients and the many 
technical limitations that often result in limited sensitivity or an inability to detect all mutations in the 
gene of interest (Carvalho et al., 2007; Grogan & Kirsch, 1997). Nowadays, the use of next generation 
sequencing (NGS) for platforms and projects has provided comprehensive gene alteration data in 
protein-coding regions for all types of human cancer. In fact, NGS based genomic sequencing has 
enabled the sequencing of individual cancer-patient genomes, and it has become, year by year, faster 
and less expensive. However, when sequencing the whole exome (the coding part) they provide us more 
information than what can be practically analysed and interpreted at a level required for clinical 
application and it is too costly for individual patient diagnosis (Nagahashi et al., 2019). Still, when 
putting the both dishes on the scale, the use of genetic testing with NGS technology is of clearly more 
vital and important for the population, mainly to individuals with a family history of breast and/or 
ovarian cancer, once the NGS-based gene panel test is the first choice for individual cancer-patient care 
(Nagahashi et al., 2019). 
Figure 1.3 - Breast cancer and genetic penetrance: List of 
genes more frequently associated with high, moderate and 
low penetrance (Mahdavi et al., 2019) 
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The results from a BRCA genetic test generally fall into three categories: (a) Positive results, 
where a pathogenic mutation is found and it provides a diagnosis or risk information; (b) Negative 
results, where no relevant genetic alteration, mutation or polymorphism, is found; or (c) VUS, or variants 
of uncertain significance, where is found a genetic alteration, but the cancer risk has not been determined 
(Hoffman-Andrews, 2017; Mahdavi et al., 2019). 
 
 
1.7 VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS) 
 
VUS, detected in 12-13% of patients tested for BRCA1 and BRCA2 mutation status, are variants 
of unknown clinical impact, and include mostly missense variants (that lead to a single amino acids 
change), but also small in-frame deletions or insertions, synonymous nucleotide substitutions, certain 
truncating mutations (such as mutations in the last exons of genes), as well as alterations in noncoding 
sequences or in untranslated regions (Mahdavi et al., 2019; Moghadasi, Eccles, Devilee, Vreeswijk, & 
van Asperen, 2016). Some of these variants behave as low-penetrance gene mutations and should not 
be treated in same way as mutations in genes with high penetrance (Mahdavi et al., 2019; Toland & 
Andreassen, 2017). It is a quite hard for a clinician to explain VUS information to patients and their 
families, once finding a VUS indicates that it was found “something” but it does not know what it means 
as far as the relationship to increased hereditary risk for developing certain cancers (Miller-Samuel et 
al., 2011). Because of this inability to classify BRCA1/2 VUS as either benign or pathogenic and to 
determine which mutations are disease causing, which generates significant problems in risk evaluation, 
counselling and preventive care, several functional assays have been or are being developed (Carvalho 
et al., 2007). These type of assays work as independent classifiers of the VUS on their protein function 
and also provide additional data that in combination with available genetic and epidemiological data can 
predict cancer causality of VUS in a likelihood model (Carvalho et al., 2007). 
Based on these assays and knowing that the process of cell division can be targeted to treat 
cancer patients, the use of genotoxic agents that initiate cell cycle checkpoints to target cancer cell 
proliferation is very useful, once they only cause  DNA damage at high levels to treat cancer patients, 
which  can lead to cell cycle arrest and/or cell death (Swift & Golsteyn, 2014). When these 
chemotherapeutics induce DNA lesions the cell must recognize and counter in order to survive using 
the DNA damage response (DDR), which will include DNA repair, suppression of global general 
translation, cell cycle arrest and, ultimately, either cell survival or cell death, as mentioned before 
(Woods & Turchi, 2013). 
As described above, germline mutations in homologous recombination (HR) DNA repair genes 
(BRCA1/2) are linked to breast and ovarian cancer, once they play an important role in their function as 
regulators of DNA repair, transcription and cell cycle in response to DNA damage (Mahdavi et al., 
2019). However, is not known that missense VUS are able to disrupt this important process. Because of 
that, VUS carriers diagnosed with metastatic breast or ovarian cancer might not benefit from therapy 
with platinum or PARP inhibitors targeting DNA-repair defects, as is currently recommended for 
individuals with BRCA1 or BRCA2 pathogenic variants (Guidugli et al., 2018; Tram, Savas, & Ozcelik, 
2013). Thus, it is so important to use functional assays to analyse VUS, which allow to assess the cells 
response to repair the damage inflicted by genotoxic chemical agents. 
 
 
1.8 CHEMOTERAPEUTIC AGENTS 
 
Among the chemotherapeutics used, Doxorubicin, an anthracycline drug, is widely used to treat 
several cancers, including BC being one of many drugs that is contained in the respective chemotherapy 
cocktail regimen. It has multiple action mechanisms on cells: (i) intercalates and interferes with DNA 
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and RNA syntheses; (ii) inhibits topoisomerase II, which leads to strand breaks on DNA; and (iii) can 
cause the formation of ROS and free radical damage on cells. All of these effects inhibit cell 
proliferation, induce the G2-M cell arrest, or lead to apoptosis (Yurtcu, Işeri, & Sahin, 2014). 
 
 
1.9 GOALS 
 
The main aim of this study is based on the functional evaluation of the role of variants of unknown 
significance (VUS), previously identified in breast cancer patients and their relatives, in drug response. 
In order to achieve this goal, we used samples of peripheral blood lymphocytes from female volunteers 
to whom was identified the same VUS and belonging to high risk families. The study was carried-out 
using a genotoxic challenge through four techniques: TUNEL assay, Caspases activity assay, H2Ax 
assay and Comet assay. With these methodologies we hypothesize that we might be able to characterize 
the VUS in cancer-related genes and give us some answers about its role in breast cancer risk. 
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2. MATERIALS AND METHODS 
 
During all experimental procedures were used appropriate consumable material according the 
experimental steps and equipment’s. 
 
2.1 OVERVIEW 
 
Over the years, genetic testing has been increasing for the identification of individuals and 
families with a genetic predisposition to developing breast cancer, the second most commonly diagnosed 
cancer. Consequently to this increase of tests, variants of uncertain significance (VUS) become more 
common in population. Once, these variants cannot be classified as either benign or pathogenic, the use 
of functional assays to assess the role of VUS may be helpful to identify its pathogenicity and 
characterization in cancer-related genes in breast cancer risk. 
 
2.2 SAMPLE SELECTION 
 
This study is composed by four female volunteers: two VUS-carriers for BRCA1 gene (VUS-
carrier 1 and VUS-carrier 2) and two negative controls (Control 1 and Control 2). The population 
enrolled was previously sequenced (Table 7.1), to confirm the variants, through NGS technology for a 
panel of BC specific genes described as essential on clinical guidelines for HBC studies, such as BRCA1 
and BRCA2.  
Each volunteer agreed with the study and signed a consent document, represented in Figure 7.1 
to Figure 7.3 of Appendix, for the use of samples for research, which it was approved by Ethical 
Commission of NMS/FCM (CEFCM). Furthermore, the VUS-carriers gave us detailed information 
about family history of oncological disease (Appendix - Figure 7.4). 
 
2.3 PREPARATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS 
(PBMCS) 
 
During the study the approaches were performed at least twice in independent experiments. For 
each single collection was drawn 20mL of peripheral blood by venous puncture. However, this amount 
is not enough to carried-out all experiments for once, which means that each donor had to draw blood 
for several times. 
PBMCs were isolated through density gradient centrifugation using Histopaque-1077 (SIGMA, 
Darmstadt – Germany), a sterile ready-to-use medium that helps at recovery of viable lymphocytes and 
other mononuclear cells from the whole blood. Briefly, blood was diluted with an equal volume of 
phosphate-buffered saline (SIGMA, Darmstadt – Germany) (PBS) and then 5mL of this diluted blood 
were carefully added to a centrifuge tube, which already contain 3.5mL of Histopaque-1077, and 
centrifuged at 700g for 30min at room temperature. At the end of that time, PBMCs were harvested 
from the interface with a Pasteur pipette to a new centrifuge tube with 7mL of PBS, to wash the cells, 
and centrifuge again at 200g for 10min. After that, the pellet was suspended in RPMI 1640 medium 
(Gibco, Waltham, MA USA) supplemented with 25% of Fetal Serum Bovine (SIGMA, Darmstadt – 
Germany), or FBS, and 1.5% of Penicillin-Streptomycin (SIGMA, Darmstadt – Germany) (Pen-Strep) 
and then, the cells were ready to use. 
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2.4 BLOOD CELL CULTURE AND MUTAGEN TREATMENT 
 
PBMCs were cultured in 12-well plates with RPMI 1640 medium supplemented with 25% of 
FBS and 1.5% of Pen-Strep. About 106 mononuclear cells were used in each assay, except H2Ax assay 
that we used about 2×106 cells. 
Mutagen treatment was performed with different incubation times, according to the optimization 
process of each assay. For each one was chosen three different concentration of Doxorubicin (Fisher 
BioReagents, Pittsburgh - USA), the genotoxic agent - 0.1, 1.0 and 5.0µM - and a positive 
(Camptothecin/H2O2) and a negative control (NC). Briefly, Camptothecin is an inhibitor of Type I 
topoisomerase that binds to DNA-TOP1 cleavage complexes, blocking re-ligation and resulting in the 
accumulation of SSBs, which leads to the activation of apoptosis, according to several studies (Swift & 
Golsteyn, 2014; Zeng et al., 2012), whereas reactive oxygen species (ROS), like H2O2, generated during 
oxidative stress only damage proteins, nucleic acids and cell membranes (Daroui, Desai, Li, Liu, & Liu, 
2004). Because of that, Camptothecin was used to be a positive control on apoptosis assays (TUNEL 
and Caspases activity assays), and H2O2 a positive control on damage assays (comet assay). 
 
2.5 FUNCTIONAL ASSAYS 
 
TUNEL assay 
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick- End Labeling (TUNEL) is an assay 
for detection of apoptotic DNA fragmentation in situ. TUNEL staining utilizes the ability of the enzyme 
terminal deoxynucleotidyl transferase (TdT) to incorporate labeled dUTP onto the free 3’-hydroxyl 
termini of fragmented genomic DNA, which can be visualized using immunohistochemical techniques 
(Kyrylkova, Kyryachenko, Leid, & Kioussi, 2012; Loo, 2011). Although TUNEL staining has been 
adopted as the method of choice for detecting apoptosis in situ, it is important to recognize that this 
assay is not limited to the detection of apoptotic cells, since this technique will label all free 3’-hydroxyl 
termini, regardless of the molecular mechanisms that led to the development of these termini, such as 
necrotic degenerating cells, cells undergoing DNA repair, cells damaged by mechanical forces and even 
cells undergoing active gene transcription. Thus, TUNEL staining should be considered generally as a 
method for the detection of DNA damage, and when used in combination with another apoptosis specific 
assay, more specifically as a method for identifying apoptotic cells (Loo, 2011). 
 
Methodology 
To carried-out TUNEL assay was used a commercial available kit by Thermo Fisher Scientific's 
APO-BrDUTM TUNEL Assay Kit. The methodology was performed according manufactures 
instructions, with minor alterations.  
Briefly, after exposure to different concentrations of the genotoxic compound to be tested, for 
4h at 37ºC with 5% CO2, the samples were centrifuged at 200g for 5min and the respective supernatant 
was discarded. 500µL of PBS was added to each sample and centrifuged at 300g for 5min. After the 
removal of supernatant, the cells were resuspended in 500µL of Formaldehyde 2% (PBS; Formaldehyde 
16% provided by Thermo Scientific, product of USA) and they were maintained for 15mins on ice. At 
the end of this time, the samples were centrifuged and each pellet was resuspended in 1mL of PBS and 
then, they are centrifuged again at 300g for 5min. The supernatant was removed, and the cells were 
resuspended in 500μl of PBS and 1mL of 70% cold Ethanol (in PBS) (PBS; Ethanol absolute provided 
by Merck, product of USA) and they were maintained for 30mins on ice. In the end, the samples were 
centrifuged to the same conditions and the supernatant removed. Then, the cells were resuspended and 
centrifuged twice with 1mL of Wash Buffer (provided in kit). Next, each pellet was resuspended in 
50µL of DNA-labeling, which contains Reaction Buffer, TdT enzyme, BrdUTP and ddH2O (each one, 
except ddH2O, provided provided in kit), and they were kept over-night at 22ºC-24ºC.  
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By the next day, the samples were resuspended and centrifuged twice with 1mL of Rinse Buffer 
(provided in kit). After removed the supernatant the cells were counted to add 100µL of a diluted 
solution, which contains Thermo Fisher Scientific's anti-BrdU mouse monoclonal PRB-1 Alexa FluorTM 
488 conjugate (provided in kit) and Rinse Buffer, and then, they were incubated for 30min at room 
temperature, protected from light. Then, the samples were analysed by flow cytometry using a FACS 
Canto II Cytometer. Image analysis were performed using the FlowJo®. 
 
Caspases activity assay 
Caspases are a family of intracellular cysteine proteases and play distinct roles in apoptosis and 
inflammation (Kaufmann et al., 2008). Based on their functions, apoptotic caspases are classified as 
initiator caspases (caspases-2, -8, -9, and -10), which transduce various signals into proteolytic activity, 
and effector caspases (caspases-3, -6, and -7), which cleave most of the substrates that are degraded in 
cells and lead to cell disassembly and consequently to apoptosis (Kaufmann et al., 2008). A current 
model suggests that caspases 8, 9, and 10 can proteolytically activate procaspases 3 and 7, which are in 
turn responsible for proteolytically activating procaspase 6. Because various initiator caspases are 
activated by different signals, identifying the caspases that are activated and their order of activation 
after treatment of cells with a particular stimulus can provide insight into the lethal signalling that is 
induced by that stimulus (Kaufmann et al., 2008).  
To detect active caspases, it is usually used Fluorochrome Inhibitors of Caspases (FLICA) that 
are cell permeable and non-cytotoxic. Once inside the cell, this inhibitor binds covalently to the active 
caspase, thereby inhibiting further enzymatic activity. Furthermore, once this inhibitor produces 
fluorescence, it is possible quantify the number of active caspases inside the cell by 96-well plate-based 
fluorometry, fluorescence microscopy, or flow cytometry. 
 
Methodology 
To carried-out Caspases assays were used a commercial available kit by CHEMICON®’s 
CaspaTag™ Caspase-3/7 In Situ Assay Kit, and CaspaTag™ Caspase-9 In Situ Assay Kit. The 
methodology was performed according manufactures instructions, with minor alterations. The 
methodology used for both assays is the same the main difference is the FLICA concentration specific 
for each one.  
Briefly, after exposure to different concentrations of the genotoxic to be tested, for 2h at 37ºC 
with 5% CO2, the samples were centrifuged at 200g for 5min and after, the respective supernatant was 
discarded. The cells were resuspended in 200µL of PBS and it was added 10µL of FLICA 6× for 
Caspases 3/7 and FLICA 15× for Caspases 9   (PBS; FLICA 150×, provided in kit) to the respective 
tubes, and they were incubated 1h at 37°C with 5% CO2, protected from light. During this time, the 
tubes were gently swirled 3 times, and after that, it was added 1mL of Wash Buffer 1× (Wash Buffer 
10×, provided in kit) and gently mixed and then, they were centrifuged at 400g for 5min. Each pellet 
was resuspended in 1mL of Wash Buffer 1× and centrifuged again at 400g for 5min. After that time, the 
pellet was resuspended in 400µL of Wash Buffer 1× and it was added 2µL of Propidium Iodide 
(provided in kit), or PI, to the respective tubes, and after, the samples were analysed by flow cytometry 
using a FACS Canto II Cytometer. Image analysis were performed using the FlowJo®. 
 
H2Ax assay 
The H2Ax assay is a based analysis marker for DNA double-strand breaks (DSBs), which it is 
both relatively robust and practical to assess Chemical and IR-induced damage in cells (Kataoka, 
Bindokas, Duggan, Murley, & Grdina, 2006). Exposure to external factors results in the rapid 
phosphorylation of a minor nucleosomal histone protein, H2Ax. The phosphorylation will serve as a 
platform for the accumulation of many factors involved in the DNA damage response. The H2Ax foci 
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formation is a sensitive and specific marker for the detection of DSBs that can be measure by fluorescent 
microscopy (Barnard et al., 2015; Dinis et al., 2012), but also by flow cytometry after a specific antibody 
reaction. 
 
Methodology 
After exposure to different concentrations of the genotoxic compounds to be tested, for 2h at 
37ºC with 5% CO2, the samples were centrifuged at 200g for 5min and the respective supernatant was 
discarded. The RPMI 1640 medium (1 ml) supplemented with 25% of FBS and 1.5% of Pen-Strep was 
added to each sample and incubated for 30min at 37°C with 5% CO2. After that time the samples were 
centrifuged and was added to the respective sample 1mL of PBS and 1μl of Violet Fluorescent Reactive 
Dye (provided by Thermo Fisher Scientific's LIVE / DEAD ™ Fixable Violet Dead Cell Stain Kit, 
product of USA) and they were incubated 30 minutes at room temperature, protected from light. Then, 
the samples were centrifuged to the same conditions and after discarding the supernatant, they were 
washed with 1 ml of PBS and centrifuged again. After that, the pellet was resuspended in 500µL of 
Formaldehyde 2% and the samples were maintained for 15min on ice. At the end of this time, they were 
centrifuged again and each pellet was resuspended in 500µL of 70% cold Ethanol (in PBS) and they 
were kept over-night at 4°C.  
By the next day, the samples were centrifuged and each pellet was resuspended in 1 ml of 
Blocking Buffer, containing Albumin from Bovine Serum (BSA) 4% (SIGMA, Darmstadt – Germany) 
in PBS, 4% Goat Serum (SIGMA, product of USA) and 0.25% Triton X-100 (SIGMA, Darmstadt – 
Germany), and were further centrifuged. The supernatant was then removed and 5μL of antibody 
(Thermo Fisher Scientific's eBioscience ™ Anti-Hu/Mo pH2AX (S139) PE (product of USA)) were 
added to the respective samples, followed by 2h of incubation at room temperature, protected from light. 
After that, the cells were washed with 1.5mL of BSA 1% and centrifuged. Then, each pellet was 
resuspended in 200μl of BSA 0.1% and after, the samples were analysed by flow cytometry using a 
FACS Canto II Cytometer. Image analysis were performed using the FlowJo®. 
 
Comet assay 
The Comet Assay, also called single cell gel electrophoresis (SCGE), is a sensitive and rapid 
technique for quantifying and analysing DNA damage in individual cells. The term comet, resulted from 
their appearance, is used to identify the single cell DNA migration. Briefly, the cells are embedded in 
agarose and then they are placed on a microscope slide. Following the slide preparation, the embedded 
cells are lysed by detergents and high salt, which promote the removal of all cellular proteins from the 
cells. Then, they are electrophoresed under alkaline conditions, allowing the broken DNA fragments or 
damaged DNA to migrate away from the nucleus, after which it is quantified by staining. The extent of 
free DNA from the head to tail of the comet is directly proportional to the amount of DNA damage 
(Fairbairn, Olive, & O’Neill, 1995; Tice et al., 2000).  
Comparing with another genotoxic assays, the comet assay: demonstrate sensitivity for 
detecting low levels of DNA damage, require a small number of cells per sample, is flexible and low 
cost, use small amounts of test substance and it’s only needed a short period of time to complete an 
experiment (Tice et al., 2000). 
 
Methodology 
After exposure to different concentrations of the genotoxic compound under test, for 2h at 37ºC 
with 5% CO2, the samples were centrifuged at 200g for 5min and the respective supernatant was 
discarded. PBS (1 ml) was added to each sample and centrifuged again. The pellet was resuspended in 
100μL of 0.5% Agarose Low Melting Point (PBS; Agarose provided by Bioline, London UK) and 40μL 
of each suspension were spread on microscope slides that were previously coated with 1% Agarose 
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Normal Melting Point. Next, they were kept for 20min at 4ºC and after that, the slides were left over-
night in cold-lysis buffer (2.5M NaCl (Fisher Scientific, Leicestershire); 100mM EDTA(SIGMA, 
Darmstadt – Germany); 10mM Tris Base (Fisher Scientific, Leicestershire); 1% Triton X-100; pH 10), 
protected from light. 
By the next day, the cold-lysis buffer was removed, and the slides were washed with cold-
double-distilled water and kept in it for 10min at 4ºC, protected from light. After that, they were 
immersed in cold-electrophoresis buffer (200mM EDTA; 10M NaOH (Acros Organics, Geel - 
Belgium.); pH≥13) for 20min at 4ºC, protected from light. After that time, the electrophoresis occurred 
at 25V for 20min and then, the slides were neutralized three times for 5min each with a neutralization 
buffer (0.4M Tris (SIGMA, Darmstadt – Germany); pH 7.5). Next, they were dried with Ethanol 50%, 
75% and 100%, 5min each, and left in a hot grid to completely dry. After, they were stained with GelRed 
Nucleic Acid Stain 3× (GelRed Nucleic Acid Stain 10.000× provided by Biotium, Fremont, CA) and 
observed with a Fluorescent Microscope (Zeiss Z2) using an ampliation of 200x, where we randomly 
selected 50 images from each slide, giving a total of 200 cells analyzed per data point. The percentage 
of DNA in Tail (% DNA in Tail) of comets was measured to assess the extent of DNA damage. Image 
analysis were performed using the CometScoreTM. 
 
2.6 BIOINFORMATICS AND STATISTICAL ANALYSIS  
 
The statistical analyses were carried out using GraphPad Prism 5 (GraphPad Software). Data 
were plotted as mean expression ± the standard deviation (SD) of replicates. The two-way analysis of 
variance (ANOVA) and post-hoc testing (Bonferroni’s multiple comparisons) were performed for 
TUNEL assay, Caspases activity assay and H2Ax assay, to compare between doses of Doxorubicin, 
positive controls and non-treated cells (0µM) and to compare between the different groups of samples. 
The one-way analysis of variance (ANOVA) and post-hoc testing (Bonferroni’s multiple comparisons) 
were performed for Comet assay to compare between doses, positive controls and non-treated cells 
(0µM), and to compare between the different groups of samples it was used the one-way analysis of 
variance (ANOVA) and post-hoc testing (Tukey’s pairwise comparisons). 
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3. RESULTS 
 
3.1 TUNEL assay 
 
To analyse the apoptosis of the cells and to clarify if VUS carrier cells had a different response 
to damage induced by genotoxic agents, we firstly determined the concentration range of Doxorubicin 
to damage or cause death to PBMCs. Through that, we used three different concentrations (0.1µM, 1µM 
and 5µM) and analysed the samples by flow cytometry. For each sample, we isolated the population of 
interest and applied the flow cytometer’s parameters that correspond with the antibody fluorescence that 
we used for TUNEL assay (Appendix - Figure 7.5 A). These results are represented in Figure 3.1 and 
Figure 3.2, where is possibly to observe an increase percentage of cells that suffered apoptosis (TUNEL-
positive cells) in all samples with increasing concentration of drug. This distribution of TUNEL-positive 
cells is represented by mean+SD and it was used the 2way ANOVA and Bonferroni post-tests to 
compare the percentage of positive cells between samples (Figure 3.1) and between doses in each sample 
(Figure 3.2). While between samples no difference statistically significant was observed for all samples, 
in between doses, VUS-carrier 2 and Control 1 and 2 showed statistical significance (p-value<0.05) 
when comparing 5µM Dox with the negative control (NC - 0µM), and only Control 1 showed statistical 
significance (p-value<0.05) when comparing 10µM CPT with the negative control (NC - 0µM). 
 
 
 
Figure 3.1 - Frequency of TUNEL-positive cells (%) for each dose of Doxorubicin. Results are 
expressed as mean+SD. Statistical analysis was performed with GraphPad Prism 5, using the two-way 
analysis of variance (ANOVA) and post-hoc testing (Bonferroni’s multiple comparisons). 
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3.2 Caspases activity assay 
 
Like TUNEL assay, this technique allowed us to analyse the apoptosis of PBMCs through three 
different concentrations of Doxorubicin and its samples were analysed by flow cytometry. After we got 
the isolated population and the correct flow cytometer’s parameters (Appendix - Figure 7.5 B), we 
represented its results in Figure 3.3 to Figure 3.8. First, we analysed the caspases-3/7 activity (Figure 
3.3 and Figure 3.4) and then, the caspases-9 activity (Figure 3.5 and Figure 3.6).  
In these two assays, we analysed the apoptotic rate (early and late apoptosis) vs necrotic rate 
and they were represented by mean+SD and it was used the 2way ANOVA and Bonferroni post-tests to 
compare the samples, represented by Figure 3.3 and Figure 3.5, and between doses in each sample, 
represented by Figure 3.4 and Figure 3.6. These results showed us statistical significance (p-value<0.05) 
in 0.1µM of Doxorubicin between samples (Figure 3.3) and in 1 and 5µM of Doxorubicin between doses 
on VUS-carriers 1 and 2 in caspases-3/7 activity (Figure 3.4). In caspases-9 activity there was only 
statistical significance (p-value<0.05) in VUS-carrier 2 when comparing the concentrations of 1 and 
5µM of Doxorubicin with the negative control (NC - 0µM), represented by Figure 3.6. 
Figure 3.2 - Frequency of TUNEL-positive cells (%) for each sample. Results are expressed as mean+SD. Statistical analysis 
was performed with GraphPad Prism 5, using the two-way analysis of variance (ANOVA) and post-hoc testing (Bonferroni’s 
multiple comparisons). *p<0.05; **p<0.01, ***p<0.001 in relationship to the negative control (NC - 0µM). 
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Figure 3.3 - Frequency of cell population (%) for each dose of Doxorubicin with Apoptotic status and Necrotic status, 
in Caspases-3/7 assay. Results are expressed as mean+SD. Apoptotic rate includes Early and Late Apoptosis and Necrotic 
rate only includes Necrosis. Statistical analysis was performed with GraphPad Prism 5, using the two-way analysis of variance 
(ANOVA) and post-hoc testing (Bonferroni’s multiple comparisons). *p<0.05; **p<0.01, ***p<0.001, in relationship to 
another sample. 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 - Frequency of cell population (%) for each sample with Apoptotic status and Necrotic status, in Caspases-
3/7 assay. Results are expressed as mean+SD. Apoptotic rate includes Early and Late Apoptosis and Necrotic rate only includes 
Necrosis. Statistical analysis was performed with GraphPad Prism 5, using the two-way analysis of variance (ANOVA) and 
post-hoc testing (Bonferroni’s multiple comparisons). **p<0.01, ***p<0.001, in relationship to the negative control (NC - 
0µM). 
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Figure 3.5 - Frequency of cell population (%) for each dose of Doxorubicin with Apoptotic status and Necrotic status, 
in Caspase-9 assay. Results are expressed as mean+SD. Apoptotic rate includes Early and Late Apoptosis and Necrotic rate 
only includes Necrosis. Statistical analysis was performed with GraphPad Prism 5, using the two-way analysis of variance 
(ANOVA) and post-hoc testing (Bonferroni’s multiple comparisons). 
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Therefore, we linked these two assays to compare between them, using the percentage of 
apoptosis. As showed in Figure 3.7 there was difference statistically significance on VUS-carrier 1, 
VUS-carrier 2 and Control 1 with 5µM of Doxorubicin (p-value<0.05), but all of them showed an 
increase of apoptosis with increasing the concentration of the drug. Furthermore, in Figure 3.8 is 
observed statistical significance (p-value<0.05) at caspase-9 and both caspases-3/7 and caspase-9, 
respectively in VUS-carrier 1 and VUS-carrier 2, for 5µM of Doxorubicin when comparing with NC 
(0µM). 
 
Figure 3.6 - Frequency of cell population (%) for each sample with Apoptotic status and Necrotic status, in Caspase-9 
assay. Results are expressed as mean+SD. Apoptotic rate includes Early and Late Apoptosis and Necrotic rate only includes 
Necrosis. Statistical analysis was performed with GraphPad Prism 5, using the two-way analysis of variance (ANOVA) and 
post-hoc testing (Bonferroni’s multiple comparisons). *p<0.05, ***p<0.001, in relationship to the negative control (NC - 0µM). 
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Figure 3.7 - Frequency of apoptotic cells (%) for each dose of Doxorubicin in Caspases-3/7 and 9 assays. Results are 
expressed as mean+SD. Statistical analysis was performed with GraphPad Prism 5, using the two-way analysis of variance 
(ANOVA) and post-hoc testing (Bonferroni’s multiple comparisons). *p<0.05, in relationship to another sample. 
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3.3 H2Ax assay 
 
This technique allowed us to analyse the damage and its respective response to different 
concentrations of Doxorubicin, like the other assays, in PBMCs from two VUS-carriers and two 
controls, and the respective samples were analysed by flow cytometry. After we got the isolated 
population and the correct flow cytometer’s parameters (Appendix - Figure 7.6), we represented its 
results in Figure 3.9 and Figure 3.10, where it is possible to observe an increase of cells that suffered 
serious damage, which caused the phosphorylation of H2Ax histone, in all samples when the drug is 
used, and according with the rise of its concentration. This distribution of H2Ax positive cells is 
represented by mean+SD and it was used the 2way ANOVA and Bonferroni post-tests to compare the 
percentage of positive cells between samples (Figure 3.9) and between doses in each sample (Figure 
3.10). While in between samples no difference statistically significance was observed, except in 
comparison of VUS-carrier 2 with Control 2 (p-value<0.05), in between doses each sample showed 
statistically significance (p-value<0.05) when comparing 5µM with NC (0µM). 
Figure 3.8 - Frequency of apoptotic cells (%) for each sample in Caspases-3/7 and 9 assays. Results are expressed as 
mean+SD. Statistical analysis was performed with GraphPad Prism 5, using the two-way analysis of variance (ANOVA) and 
post-hoc testing (Bonferroni’s multiple comparisons). *p<0.05; **p<0.01, ***p<0.001, in relationship to the negative control 
(NC - 0µM). 
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Figure 3.9 - Frequency of H2Ax (%) for each dose of Doxorubicin. Results are expressed as mean ± SD. Statistical analysis 
was performed with GraphPad Prism 5, using the two-way analysis of variance (ANOVA) and post-hoc testing (Bonferroni’s 
multiple comparisons). **p<0.01 in relationship to another sample. 
 
Figure 3.10 - Frequency of H2Ax (%) for each sample. Results are expressed as mean+SD. Statistical analysis was 
performed with GraphPad Prism 5, using the two-way analysis of variance (ANOVA) and post-hoc testing (Bonferroni’s 
multiple comparisons). ***p<0.001 in relationship to the negative control (NC - 0µM). 
 
 
22 
 
3.4 Comet assay 
 
Like H2Ax assay, this technique allowed to analyse the response to damage in PBMCs through 
different concentrations of Doxorubicin and the samples were analysed by fluorescent microscopy with 
200x ampliation. In each slide, we randomly select 50 images, giving a total of 200 cells on each dose, 
represented on Figure 3.11. In some cases, the number of cells was not reached, but the maximum limit 
was kept on 200 cells. After we got the images, each one of them was analysed by the CometScore 
Software that returned the percentage of DNA in Tail (% DNA in Tail) of the cells. This distribution of 
DNA in Tail is represented by mean and it was used the 1way ANOVA and, Tukey and Bonferroni post-
tests to compare the percentage of DNA in Tail between samples (Figure 3.12) and between doses in 
each sample (Figure 3.13). In Figure 3.12 it was observed statistical significance (p-value<0.05) between 
some samples in each dose, except 1µM of Doxorubicin. Furthermore, in Figure 3.13 it was observed 
difference statistically significance (p-value<0.05) between some doses in all samples, except in VUS-
carrier 2. It is important to mention that this was the only assay, where we performed one independent 
experiment for each sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 3.11 - Representative images of cells captured for comet assay. (A) 
Normal cells with DNA in nucleus; (B) Damaged cells with migration of DNA 
creating “comets”. 
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Figure 3.12 - Distribution of DNA in Tail (%) for each dose of Doxorubicin. Results are expressed as mean ± SD. Statistical 
analysis was performed with GraphPad Prism 5, using the one-way analysis of variance (ANOVA) and post-hoc testing 
(Tukey’s pairwise comparisons). *p<0.05; **p<0.01, ***p<0.001 in relationship to another sample. 
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Figure 3.13 - Distribution of DNA in Tail (%) for each sample. Results are expressed as mean+SD. Statistical analysis was 
performed with GraphPad Prism 5, using the one-way analysis of variance (ANOVA) and post-hoc testing (Bonferroni’s 
multiple comparisons). *p < 0.05; ***p<0.001 in relationship to the negative control (NC - 0µM). 
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4. DISCUSSION 
 
Nucleic acids are the most sensitive biologic molecules to chemical reactions, which means that 
when seriously damage might contribute to increase the genomic instability in cells (Hoeijmakers, 
2009). Particularly in DNA, this damage can be from endogenous and exogenous agents that 
consequently involve one (SSB) or both (DSB) strands of the molecule. To avoid genomic instability, 
one of the hallmarks of cancer, DNA damage is repaired by DDR or damaged cells are eliminated by 
death mechanisms (Nowsheen & Yang, 2013; Roos & Kaina, 2006). The most important error-free DNA 
DSB repair mechanism is HR that align DSBs ends prior to ligation and an alteration in this pathway, 
mainly promoted by BRCA1 mutation, it destabilizes the genomic maintenance and confer an increased 
risk of developing breast cancer (Helena et al., 2018; Mahdavi et al., 2019; Roos & Kaina, 2006). To 
overcome the disease is essentially to perform genetic tests that identify individuals and families with 
higher genetic predisposition to develop cancer, such as BRCA1 and BRCA2. One of the possible results 
from genetic tests is VUS, or variants of uncertain significance, that cannot be classify as benign or 
pathogenic alteration, which generates significant problems in risk evaluation, counselling and 
preventive care (Carvalho et al., 2007; Hoffman-Andrews, 2017; Mahdavi et al., 2019). With this in 
mind, we performed four functional assays that enable to assess cell response to repair the damage 
inflicted by genotoxic agents in peripheral blood lymphocytes from two VUS-carriers patients in the 
BRCA1 gene (VUS-carrier 1 and 2) and two controls (Control 1 and 2), without any variant detected 
after sequencing analysis. These samples were treated with Doxorubicin, an anthracycline drug widely 
used to treat several cancers, which intercalates and interferes with DNA and RNA syntheses, inhibits 
topoisomerase II, which leads to strand breaks on DNA, and can cause the formation of ROS and free 
radical damage on cells, and all of them, furthermore, lead to apoptosis (Yurtcu et al., 2014). Then the 
response to damage was assessed by TUNEL assay, Caspases activity assay, H2Ax assay and Comet 
assay. 
TUNEL assay is a method used for localization of apoptotic DNA fragmentation in situ, 
although it can be used as well as an assay for the detection of DNA damage (Kyrylkova et al., 2012; 
Loo, 2011). With this technique it was possible to observe, in Figure 3.2, statistical significance for 5µM 
of Doxorubicin at VUS-carrier 2 and both Controls 1 and 2, when comparing with negative control (NC 
- 0µM), and an increase of TUNEL-positive cells from negative control (NC - 0µM) to 5µM of 
Doxorubicin only in VUS-carrier 2 and Control 2 and not in all of them as expected, which can be 
explained by intra-individual variability that exist in this study, proved by the high SD observed in VUS-
carrier 1 and Control 1. Furthermore, we worked with living cells (PBMCs) from different persons in 
different time periods, which exponentially increase this variability, along with other aspects of the 
human conditions that can influence the normal gene expression (Whitney et al., 2003). When observing 
the graph in Figure 3.1, we do not observe any difference statistically significance, but we can observed 
that both Controls 1 and 2 had the highest population of positive cells, compared with VUS-carriers 1 
and 2. This is also observed in micronuclei assay described in the master’s thesis “Functional 
Characterization of Variants of Unknown Significance in Familial Breast Cancer” by Rita Lourenço, a 
previous work developed by our group. Based on that, due to the acute exposure of genotoxicity 
employed in blood cells, they do not have the skill to repair the damage inflicted and thus, there is an 
excessive amount of genome damage that accumulated. And so, cells with that excessive damage are 
eliminated by apoptosis (Bonassi et al., 2007). Due these results it is possible to assume that cells from 
VUS-carrier 1 and 2, with an excessive genome damage are eliminated by apoptosis, but less than the 
quantity of apoptotic cells provided by Control 1 and 2. If a VUS from BRCA1 gene had biologic 
meaning these results are not the expected, once Control 1 and 2 had, theoretically, less sensitivity to 
damage than VUS-carrier 1 and 2, guiding to a lower apoptosis activity, but once we do not know its 
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biologic meaning, this assay should be perform once again, and with more apoptosis assays to see what 
is it will be the correct answer. Additionally, our positive control of drug (10µM CPT), only show 
statistical difference, in Figure 3.2, for Control 1 and with a higher SD. This is not expected, once 10µM 
CPT should be able to promote the apoptosis of cells at highs levels, and not minimum levels as we see. 
To eliminate the variability that can mask the results and to ensure the veracity of the results, more 
assays should be performed in the future, and maybe with a dose of CPT more efficient. 
The caspases activity assay has been used to detect active caspases, proteases linked to 
apoptosis, which allow to quantify cells that suffered serious damage leading to a higher level of 
apoptotic cells (Kaufmann et al., 2008). When analysing the activity of capases-3/7 in Figure 3.4, it is 
possible to see an increase of apoptotic activity by increasing the concentration of Doxorubicin for all 
samples, except Control 1, not showing any difference statistically significance between the doses. 
However, when comparing between samples, in Figure 3.3, they show statistical significance (p-
value<0.05) in 0.1µM of Doxorubicin between all samples, except between VUS-carrier 1 and Control 
1. This result may indicate a sensitivity of samples at lower doses of Doxorubicin, and once again the 
existence of genetic variability, in this case inter-individual variability. Additionally, the positive control 
for apoptosis (10µM CPT) does not show high levels of apoptosis compared with Doxorubicin. 
However, it is observed that the levels of apoptosis is higher than the necrotic levels, what is expected, 
once CPT promote cellular apoptosis, as mentioned before (Swift & Golsteyn, 2014; Zeng et al., 2012). 
In caspase-9 activity analysis, when observing Figure 3.6, there is only statistically significance 
(p-value<0.05) in apoptotic activity at higher doses of Doxorubicin in VUS-carrier 2, however it is 
visible that apoptosis increases by increasing the concentration of Doxorubicin for all samples.  
Furthermore, in Figure 3.5 it is possible to observe that there is not statistical significance between 
samples, which may indicate that both VUS-carriers and Controls do not have a higher difference at 
apoptosis activity. However, Controls have less apoptosis than the VUS-carriers, and because of that it 
is necessary to perform more assays to confirm our observational data. Additionally, the positive control 
for apoptosis (10µM CPT) does not show high levels of apoptosis compared with Doxorubicin, like the 
Caspases-3/7 assay, but show as the last one, high levels of apoptosis compared with necrotic rate. 
When combining these two caspases activity assays, it is possible to see, in Figure 3.7, that both 
caspases-3/7 and caspase-9 do not have statistical difference until 5µM of Doxorubicin, where caspase-
9 have a higher apoptotic activity when comparing with caspases-3/7, with a statistically significance 
(p-value<0.05) in all samples, except Control 2. This is explained by caspases pathway, where pro-
caspase-9 is recruited and activated by the apoptosome to active effector caspases, like caspase-3 and -
7, and trigger a cascade of events leading to apoptosis. So, it is this bonding between pro-caspase-9 and 
apoptosome that promote the significant activity observed in this figure. Additionally, once caspases-
3/7 are later activated and they not remain binding to apoptosome, its activity decrease (Li et al., 2017; 
Wu & Bratton, 2017). 
Additionally, when analysing the influence of Doxorubicin in Figure 3.8, VUS-carriers 1 and 2 
showed a statistical difference (p-value<0.05) with negative control (NC - 0µM) at 5µM of Doxorubicin 
in both caspases, except caspases-3/7 in VUS-carrier 1. Neither of the Controls shows statistical 
difference after the treatment, which it is expected and might be associated with less sensitivity to the 
drug than that exists in BRCA1 VUS cells, where maybe there is a defective in DNA repair by 
homologous recombination. Furthermore, 10µM CPT does not show high levels of apoptosis, compared 
with Doxorubicin, and being the positive control for apoptosis it is not expected these results. Therefore, 
in future assays it is essential to use a dose more efficient of CPT, or even another drug to be our positive 
control. 
The apoptotic activity obtained by TUNEL assay and by Caspases activity assay shows a 
difference between the results. While, at higher concentrations in TUNEL assay there is a bigger value 
of apoptosis for Controls 1 and 2, compared with VUS-carriers 1 and 2, in Caspases activity assay there 
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is the opposite, even VUS-carriers 1 and 2 had statistical difference at 5µM of Doxorubicin. These 
differences can be related with the sensitivity of each technique and with the genetic variability, 
mentioned before. Because of that, it is essential to perform more experiments in each technique, 
knowing that we always take the risk that the donor may limit availability to the study by asking for 
more blood draws.  
The H2Ax assay has been used to assess Chemical and IR-induced damage in cells, once it is 
a based analysis marker for DNA double-strand breaks (DSBs) (Kataoka et al., 2006). When analysing 
the influence of Doxorubicin, in Figure 3.10, every samples showed statistically significance (p-
value<0.05) in comparison between 5µM of Doxorubicin and negative control (NC - 0µM), and each 
one shows an increase of H2Ax phosphorylated by increasing the concentration of Doxorubicin. 
However, it is showed that Controls 1 and 2 have lower values, compared with VUS-carriers 1 and 2, 
but due to the high SD observed for the highest dose it is assumed the existence of intra-individual 
variability. When comparing between samples (Figure 3.9), there is only statistical difference (p-
value<0.05) between VUS-carrier 2 and Control 2 at 5µM of Doxorubicin, where the VUS-carrier 2 
shows more damage (more H2Ax phosphorylated) than Control 2. This is may indicate that Control 2 
has less sensitivity to the drug than the VUS-carrier 2, which it may be related with a defective in DNA 
repair in this last one. However, there is intra-individual variability at least in Control 2, due the high 
SD, which does not clarify the correct results. Additionally, in this assay we should have used a positive 
control for quantify the DNA damage and the DSBs, like Ionizing radiation, which it is a type of high-
energy radiation that is able to release electrons from atoms and molecules generating ions that can 
break covalent bonds. This type of radiation directly affects DNA structure and induces DNA breaks, 
particularly, DSBs (Borrego-Soto, Ortiz-López, & Rojas-Martínez, 2015). Once we do not used it, we 
do not know if the results that we obtained are related with the VUS or with the treatment,  and because 
of that it is crucial make more assays, this time with a positive control that we know for sure that induce 
DSBs, to the correct understanding of the results. 
Comet assay, like H2Ax assay, has been used for quantifying and analysing DNA damage in 
individual cells (Fairbairn et al., 1995; Tice et al., 2000). When analysing Doxorubicin’s influence 
(Figure 3.13) VUS-carrier 1 and Control 1 showed statistical significance (p-value<0.05) with negative 
control (NC - 0µM) at 5 and 10µM of Doxorubicin, with VUS-carrier 1 had higher values compared 
with Controls 1 and 2, even this last one did not show statistical difference between doses. However, for 
sample VUS-carrier 2 we should be expecting more damage after the treatment, just like VUS-carrier 1, 
but instead it shows no visible difference between concentrations, which can be explained by inter-
individual variability and not directly related to the presence of VUS. When comparing between 
samples, in Figure 3.12, is much evident that at highest doses (5 and 10µM of Doxorubicin), VUS-
carrier 1 and 2 shows statistical difference in comparison with Controls 1 and 2. However, this figure 
shows the inter-individual variability that exists between VUS-carriers and between Controls. Even that, 
VUS-carrier 1 shows more DNA in tail than Controls 1 and 2, which it may indicate that Controls have 
less sensitivity than the VUS-carrier 1 and that is possibly related with the defective in DNA repair. 
Additionally, our positive controls for DNA damage (10µM, 25µM and 50µM of H2O2) show statistical 
significance between some samples, showing that VUS-carrier 2 and Control 2 had similar results. In 
this case, inter-individual variability is observed again between VUS-carriers and between Controls. 
Because of these strange results, it is essential perform more assays to correct understanding the results. 
When comparing the results of both techniques there is some differences. While in H2Ax assay, 
all samples have statistical difference between 5µM of Doxorubicin and negative control (NC - 0µM), 
in Comet assay, only VUS-carrier 1 and Control 1 show that. Furthermore, instead of had statistical 
difference between samples at 5µM, like Comet assay has, in H2Ax assay there is only one statistical 
difference and between VUS-carrier 2 and Control 2. Additionally, VUS-carrier 2 shows two different 
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behaviours, with the highest values for damage in the H2Ax assay, while in Comet assay, the sample 
shows a behaviour similar to a negative control, almost without any difference between doses, even with 
the positive controls (10µM, 25µM and 50µM of H2O2). These differences may possible indicate inter- 
and intra-individual variabilities, like it was mentioned before, and maybe the existence of bias that we 
could not control, once each donor had to draw blood for several times for the several assays. 
 Even these differences, in both assays both Controls show less damage than VUS-carrier 1, and 
the damage increase in all these three samples by increasing the dose of Doxorubicin. This may indicate 
again that Controls had less sensitivity than VUS-carriers, and that sensitivity is possibly associated with 
a defective in DNA repair. However, more assays should be performed to assess the real picture of VUS-
carrier 2 and confirm the results obtained.  
In fact, our results were not conclusive concerning the biological role of VUS under study, and 
didn’t let us state about its pathogenicity. Further studies shall be conducted that help us to confirm the 
clinical relevance of this VUS detected in BRCA1 gene. 
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5. CONCLUSION 
 
Over the years, breast cancer become the second most commonly diagnosed cancer worldwide 
and to overcome this problem genetic testing become essential for the identification of individuals and 
families with a genetic predisposition to developing cancer. With an increase of these tests, the appearing 
of VUS has become more common among the population. These variants cannot be classified as either 
benign or pathogenic, due to its inability to classify BRCA1/2 VUS and to determine which mutations 
are disease causing, which generates significant problems in risk evaluation, counselling and preventive 
care. Because of that are functional assays so important, once they work as independent classifiers of 
the VUS on their protein function, which can predict cancer causality of VUS in a likelihood model.  
There are several functional assays, but in this study we only four of them: TUNEL assay, 
Caspases activity assay, H2Ax assay and Comet assay. All of them showed some differences in all 
samples that may indicate the existence of intra- and inter-individual variability, due the fact that we 
used living cells (PBMCs) from the patients, which limit the cell supply. As expected, all experiments 
showed an increase of sensitivity by increasing the dose of the drug, and all of them, except TUNEL 
assay, showed a less sensitivity in Controls than the VUS-carrier 1 in drug response, which possibly be 
associated with a defective in DNA repair in VUS-carriers. VUS-carrier 2, on its turn, shows some 
results not expected, maybe because of genetic variability, even in positive controls. Because of that is 
not clear the real picture of VUS-carriers and if VUS has an important role in DNA repair. Concerning 
such fact, and even our results didn’t allow us to hypothesize about the biologic risk of the VUS under 
study, left our mind aware to create new questions to explain the results here shown. 
Thus, more assays should be performed to remove the genetic variability and to correlate all 
techniques in one answer that could us help to characterize the highly frequent VUS in cancer-related 
genes.  
Due the fact that the biggest limitations of using Peripheral Blood Mononuclear Cells (PBMCs) 
are the recurrent blood collection by venous puncture from our patients, and the limited cell supply, 
mentioned before, make this a methodology invasive to the patients and to their families. Because of 
that we intend to establish human B lymphoblastic cell lines, derived from our patients, using Epstein-
Barr virus, which it is going to overcome all of these problems. Furthermore, to help us on the 
characterization of highly frequent VUS in cancer-related genes detected by clinical panels through NGS 
platforms, we intend to use a breast cancer cell model (MCF-10A) that has been transformed through 
gene editing, CRIPSR-Cas9 approach, by introducing the VUS of interest in the cell-line genome. Then, 
functional assays will be performed exposing the cell model to different chemotherapeutic compounds 
such as: PARP inhibitors analogues, doxorubicin and platinum analogues, to evaluate their cytotoxic 
and genotoxic effects. 
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7. APPENDIX 
 
 
 
 
Figure 7.1 - Study’s information delivered to the donors. 
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Figure 7.2 - Informed consent filled and signed by donors. 
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Figure 7.3 - Questionnaire filled and signed by donors. 
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Table 7.1 - Results obtained from sequencing with the alteration present in each donor and probable outcomes predicted. 
ID Age Cancer 
Family 
History 
Gene VUS EBI amino/genomic rs 
Cons. 
Type 
PolyPhen Clin. Signif. Diagnosis 
VUS-
carrier 
1 
25 Healthy Yes BRCA1 
NM_007294.3:c.1067A>G 
NM_007297.3:c.926A>G 
ENSP00000350283.3:p.Gln356Arg   
17:g.43094464T>C 
rs1799950 Missense 
probably 
damaging(0.969) 
Benign Benign 
VUS-
carrier 
2 
39 Healthy Yes BRCA1 NM_007294.3:c.1067A>G 
ENSP00000418960.2:p.Gln356Arg  
17:g.43094464T>C 
rs1799950 Missense 
possibly 
damaging(0.795) 
Benign Benign 
  
 
          
 
I.1. Unknown Cancer; ? 
II.1. Chronic Thrombocytopenia; 69y 
II.2. Ovarian Cancer; >50<60y 
III.1. Healthy; Mutation Carrier; 39y 
VUS Carrier 2 
I.1. Prostate Cancer; ? 
II.1. Esophageal Cancer; 75y 
II.2. Prostate Cancer; 80y 
III.1. Hypophysis Adenoma; 50y 
III.2. Tumoral Mass Intraperitoneal; 65y 
IV.1. Healthy; Mutation Carrier; 25y 
IV.2. Thyroid Carcinoma; 20y 
VUS Carrier 1 
Figure 7.4 - Pedigree Diagrams and family history of samples VUS-carrier 1 and VUS-carrier 2. 
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Figure 7.5 - The experimental batch of sample preparation using PBMCs. (A) TUNEL assay; (B) Caspases 
activity assay. 
A 
B 
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Figure 7.6 - The experimental batch of sample preparation for the 
H2AX assay using PBMCs. 
